Karen Fulwood, NP
Psychiatric/Mental Health · Myrtle Beach, SCNPI 1164414520
Payments from drug & device makers
Across 853 payments — averaging $35.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- plus $6K from 19 others
What the payments were for
- Speaking & faculty fees$11,85039%
- Travel & lodging$2,0337%
- Food & beverage$16,28354%
- Education$660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 210 | $16,780 |
| Teva Pharmaceuticals USA, Inc. | 159 | $2,054 |
| Otsuka America Pharmaceutical, Inc. | 78 | $1,730 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $1,332 |
| Neurocrine Biosciences, Inc. | 55 | $1,240 |
| Vanda Pharmaceuticals Inc. | 40 | $1,236 |
| Alkermes, Inc. | 43 | $1,170 |
| Axsome Therapeutics, Inc. | 34 | $901 |
| Johnson & Johnson | 34 | $848 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $511 |
| Lundbeck LLC | 16 | $403 |
| Eisai Inc. | 20 | $358 |
| E.r. Squibb & Sons, L.L.C. | 16 | $341 |
| Sunovion Pharmaceuticals Inc. | 14 | $324 |
| Corium, LLC | 14 | $257 |
| Idorsia Pharmaceuticals US Inc | 6 | $178 |
| Merck | 7 | $134 |
| Ironshore Pharmaceuticals Inc. | 4 | $87 |
| Avanir Pharmaceuticals, Inc. | 5 | $76 |
| Acadia Pharmaceuticals Inc | 3 | $59 |
| Noven Therapeutics, LLC | 2 | $49 |
| Indivior Inc. | 2 | $45 |
| OWP Pharmaceuticals, Inc. | 2 | $43 |
| Bausch Health US, LLC | 2 | $39 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$13,809
- ARISTADA$876
- LYBALVI$644
- Fanapt$458
- REXULTI$245
- INVEGA SUSTENNA$164
- INVEGA TRINZA$164
- Austedo XR$124
- CAPLYTA$121
- Auvelity$119
- QUVIVIQ$117
- INGREZZA$114
- SPRAVATO$100
How this compares
$30,232 in reported general payments places this provider in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 36 | $351,677 |
| VraylarCariprazine Hcl | 75 | $132,955 |
| IngrezzaValbenazine Tosylate | 14 | $118,166 |
| RexultiBrexpiprazole | 46 | $78,126 |
| AustedoDeutetrabenazine | 11 | $61,251 |
| Abilify MaintenaAripiprazole | 15 | $49,946 |
| CaplytaLumateperone Tosylate | 12 | $22,648 |
| VyvanseLisdexamfetamine Dimesylate | 39 | $14,914 |
| TrintellixVortioxetine Hydrobromide | 21 | $13,431 |
| Aripiprazole | 80 | $12,835 |
| BelsomraSuvorexant | 14 | $10,079 |
| Lurasidone Hcl | 20 | $9,504 |
| Lisdexamfetamine Dimesylate | 45 | $8,921 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 157 | $5,771 |
| Chlorpromazine Hcl | 55 | $5,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $2,054 | $412,92847 claims |
| AbbVieVraylar | $16,780 | $132,95575 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,730 | $128,07261 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,240 | $118,16614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $511 | $28,34560 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,332 | $22,64812 claims |
| MerckBelsomra | $134 | $10,07914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Myrtle Beach
- Cristina GabrielMyrtle Beach$10K
- Donna SmolenskiMyrtle Beach$8K
- Anna BorsicMyrtle Beach$6K
- Tara Davis-BoydMyrtle Beach$4K
- Robin StarrMyrtle Beach$3K
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
- Cerrissa HugieCharleston$54K
- Taylor CrewsIsle Of Palms$28K
- Lauren DyerGreenville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.